Pfizer’s $4.9bn bet on obesity startup Metsera is looking promising, with 14.1% weight loss reported in a Phase IIb trial. In the VESPER-1 trial (NCT06712836), MET-097i, a glucagon-like peptide-1 ...
News Medical on MSN
George Mason University leads phase 2 clinical trial for pill to help maintain weight loss after GLP-1s
GLP-1 medications like Ozempic and Wegovy have transformed obesity treatment, but maintaining weight loss after the medications stop remains a challenge. George Mason University is leading a new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback